As a brain cancer physician and a physician investigator, I could not be more excited about May being Brain Cancer Awareness Month,” says Ahluwalia in an interview with Targeted OncologyTM. Ahluwalia ...

The FDA Oncologic Drug Advisory Committee meetings on Tuesday and Wednesday discussed therapies across lymphoma, multiple myeloma, bladder cancer, and prostate cancer.

Final overall survival (OS) results from the INAVO120 trial (NCT04191499) confirmed that the addition of inavolisib (Itovebi) ...

As the oncology community prepares for the 2025 American Society of Clinical Oncology Annual Meeting, anticipation is running ...

In an interview, Aditya Shreenivas, MD, MS, discussed the approval of penpulimab in nasopharyngeal carcinoma and the study ...

Statin use in CLL/SLL patients showed improved survival regardless of treatment, suggesting repurposing potential for this ...

AI-assisted training notably improved pathologist accuracy in HER2-low breast cancer, reducing misclassification and ...

Manmeet Ahluwalia, MD, MBA, FASCO, discussed the significance of National Cancer Research Month and highlighted how ongoing ...

Neel Shah, MD, our first 2025 Oncology Icon, reflected on his journey from academic medicine to community oncology.

David P. Carbone, MD, PhD, discusses the outcomes of the phase 3 CheckMate 9LA trial in non–small cell lung cancer based on ...

In an interview, Prof Martin Dreyling discussed the approval of first-line acalabrutinib for the treatment of adult patients ...

Long-term data confirms early rituximab significantly delays new treatment for advanced, asymptomatic, low-burden follicular ...